中文

Traphaco

TRA HOSE Health Care
₫37,000
+0.00% 2026-09-15 · Close
AI Composite Signal
10.0 / 10
Very Bullish — 5-signal composite
Mkt Cap
3.2T
₫3.2T
P/E
11.1
P/B
2.1
ROE
19.0%
ROA
12.4%
EPS
7.2K
Price Chart
What matters now

Traphaco (TRA) is a company in Vietnam's Health Care sector, listed on HOSE. The stock last traded at 37,000 VND, little changed on the session, giving a market capitalization of 3.2 trillion VND.

On valuation, TRA trades at a price-to-earnings ratio of 11.1 and a price-to-book of 2.1. That is a discount to the Health Care sector average P/E of 18.9. Return on equity of 19.0% points to solid profitability relative to the company's equity base, above the sector average of 11.5%. Trailing earnings per share stand at 7,211 VND.

Aveluro tracks 9 news items mentioning TRA, where recent coverage skews positive (56% of articles). The most recent catalyst was a stake change event — "SCIC to Divest Stakes in 66 Firms, Retains VNM, SAB, FPT in 2026-2030 Plan". Aveluro's composite model rates TRA 10.0/10 (Very Bullish), blending news sentiment, price momentum, and fundamentals.

Comparable names in the Health Care sector include AGP, AMP and AMV.

Latest catalyst

SCIC to Divest Stakes in 66 Firms, Retains VNM, SAB, FPT in 2026-2030 Plan

Recent Developments

Recent developments around Traphaco include 5 notable classified events. On Aug 13, 2026, a market event was reported: SCIC's 2026-2030 restructuring plan targets full divestment from 66 enterprises, potentially adding significant supply to the market, while retaining stakes in 21 firms including Vinamilk (VNM), Sabeco (SAB), and FPT. On Jul 31, 2026, an earnings beat was reported: POW reported Q2 2026 pre-tax profit of VND 4,152 billion, up 413% year-on-year, lifting H1 profit to VND 5,559 billion (+321%). On Jul 18, 2026, a dividend announcement was reported: CTG and VCB will each disburse over VND 3,000 billion in cash dividends at 4.5% rate, with ex-date July 23 and 24 respectively. On May 13, 2026, a market event was reported: Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. A recent a market event was reported: IMP is now majority-owned by China's Livzon after a VND 6,000B deal for 67.87% of shares.

The overall tone of recent coverage is positive, with 2 of 5 events carrying bullish sentiment.

AI Signal Breakdown
Bearish Neutral Bullish
10.0 / 10
Very Bullish
Sentiment
+1.00
Impact
0.30
Momentum
+0.14
Fundamentals
+1.00
Volume
1.00
Sentiment 30% · Impact 20% · Momentum 20% · Fundamentals 15% · Volume 15%
News Sentiment
9
Articles Analyzed
Positive 5
Neutral 4
Recent News
Aug 13, 2026 Full Analysis Neutral stake change
SCIC's 2026-2030 restructuring plan targets full divestment from 66 enterprises, potentially adding significant supply to the market, while retaining stakes in 21 firms including Vinamilk (VNM), Sabeco (SAB), and FPT. The list is flexible, so actual divestment pace will vary by company and market conditions.
Jul 31, 2026 Full Analysis Positive earnings beat
POW reported Q2 2026 pre-tax profit of VND 4,152 billion, up 413% year-on-year, lifting H1 profit to VND 5,559 billion (+321%). VNZ also surged 701% in Q2, while BCM and DXS posted sharp declines, highlighting divergent earnings across HOSE-listed sectors.
Jul 18, 2026 Full Analysis Positive dividend announcement
CTG and VCB will each disburse over VND 3,000 billion in cash dividends at 4.5% rate, with ex-date July 23 and 24 respectively. DBM pays the highest rate at 35%, benefiting major shareholder TRA.
May 13, 2026 Full Analysis Neutral sector sentiment
Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. The sector is projected to double from $8-9 billion to $16 billion by 2032, driving M&A interest.
Full Analysis Neutral m a announcement
IMP is now majority-owned by China's Livzon after a VND 6,000B deal for 67.87% of shares. The acquisition gives Livzon control of IMP's 12 EU-GMP production lines, a rare asset in Vietnam.
Related Stocks — Health Care
Stock Analysis

By Aveluro Research Team · Editorial policy · Caveat: Not investment advice. · How Aveluro computed this

Information provided for educational purposes only. Past performance does not guarantee future results. Data sourced from public Vietnamese market feeds.

Last updated: 2026-09-15T16:36:26Z.